Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch

As Incyte Corporation’s recently-minted Opzelura gets off to the races in eczema, the drug has run up against a setback in another dermatology indication.

Related Keywords

,Incyte ,Opzelura ,Jakafi ,Jak Inhibitors ,Topical Drug Delivery ,Eczema ,Atopic Dermatitis ,Nda Application Process ,Fierce Pharma Homepage ,Pharma ,